1. Search Result
Search Result
Results for "

Dementia

" in MedChemExpress (MCE) Product Catalog:

77

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

20

Natural
Products

5

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N7421

    Others Neurological Disease
    Smilagenin acetate is a sapogenin derivative extracted from patent US20030004147A1. Smilagenin acetate increases the expression of acetylcholine m2 receptors and can be used for the research of dementia .
    Smilagenin acetate
  • HY-148108

    Cholinesterase (ChE) Neurological Disease
    AChE-IN-27 (compound 8c) is an AChE inhibitor (IC50=0.19 µM). AChE-IN-27 can be used in studies of neurological diseases such as alzheimer's disease, dementia, ataxia and myasthenia gravis .
    AChE-IN-27
  • HY-135653A

    (Rac)-BPN-19186

    Epoxide Hydrolase Neurological Disease
    (Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) extracted from patent WO2019156991A1, page 39, has a Ki of 0.06 nM. (Rac)-EC5026 can be used for the research of Parkinson's disease and dementia with Lewy Bodies (DLB) .
    (Rac)-EC5026
  • HY-N7699B

    Others Neurological Disease
    D-Tetramannuronic acid, an alginate oligomer, is produced by marine brown algae and by a limited range of Gram negative bacteria. D-Tetramannuronic acid can be used for the research of pain and vascular dementia .
    D-Tetramannuronic acid
  • HY-N7699C

    Others Neurological Disease
    D-Pentamannuronic acid, an alginate oligomer, is produced by marine brown algae and by a limited range of Gram negative bacteria. D-Pentamannuronic acid can be used for the research of pain and vascular dementia .
    D-Pentamannuronic acid
  • HY-107803

    Estrogen Receptor/ERR Neurological Disease
    Geranium oil serves as a partial agonist for estrogen receptor (ER), enhancing both the cytotoxicity induced by Tamoxifen (TMX) (HY-13757A) in GT1-7 cells and the adverse effects of TMX on the central nervous system. Geranium oil can be utilized in the research of neurological disorders such as dementia .
    Geranium oil
  • HY-N0505

    Monoamine Oxidase Neurological Disease
    Rosiridin inhibits MAO A and MAO B with potential beneficial effect in depression and senile dementia. Rosiridin shows an inhibition of 83.8% against MAO B at 10 μM (pIC50=5.38) .
    Rosiridin
  • HY-113745

    Others Neurological Disease
    LX-6171 is an orally active SLC6A7 inhibitor. LX-6171 can be used to study diseases characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia .
    LX-6171
  • HY-N7699A

    TNF Receptor Neurological Disease Inflammation/Immunology
    D-Trimannuronic acid, an alginate oligomer is extracted from seaweed. D-Trimannuronic acid can induce TNF‐α secretion by mouse macrophage cell lines. D-Trimannuronic acid can be used for the research of pain and vascular dementia .
    D-Trimannuronic acid
  • HY-N7699D

    Others Neurological Disease
    D-Hexamannuronic acid, an alginate oligomer, is produced by marine brown algae and by a limited range of Gram negative bacteria. D-Hexamannuronic acid can be used for the research of pain and vascular dementia .
    D-Hexamannuronic acid
  • HY-N7699E

    Others Neurological Disease
    D-Heptamannuronic acid, an alginate oligomer, is produced by marine brown algae and by a limited range of Gram negative bacteria. D-Heptamannuronic acid can be used for the research of pain and vascular dementia .
    D-Heptamannuronic acid
  • HY-N7699F

    Others Neurological Disease
    D-Octamannuronic acid, an alginate oligomer, is produced by marine brown algae and by a limited range of Gram negative bacteria. D-Octamannuronic acid can be used for the research of pain and vascular dementia .
    D-Octamannuronic acid
  • HY-N7699G

    Others Neurological Disease
    D-Nonamannuronic acid, an alginate oligomer, is produced by marine brown algae and by a limited range of Gram negative bacteria. D-Nonamannuronic acid can be used for the research of pain and vascular dementia .
    D-Nonamannuronic acid
  • HY-153427

    Tau Protein Neurological Disease
    Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies .
    Tau protein aggregation-IN-1
  • HY-B1124
    Fipexide
    1 Publications Verification

    Adenylate Cyclase Dopamine Transporter Neurological Disease
    Fipexide, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide reduces striatal adenylate cyclase activity. Fipexide has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide is used for senile dementia research. Fipexide acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection .
    Fipexide
  • HY-B1124A
    Fipexide hydrochloride
    1 Publications Verification

    Adenylate Cyclase Dopamine Transporter Neurological Disease
    Fipexide hydrochloride, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide hydrochloride reduces striatal adenylate cyclase activity. Fipexide hydrochloride has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide hydrochloride is used for senile dementia research. Fipexide hydrochloride acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection .
    Fipexide hydrochloride
  • HY-B1124R

    Adenylate Cyclase Dopamine Transporter Neurological Disease
    Fipexide (Standard) is the analytical standard of Fipexide. This product is intended for research and analytical applications. Fipexide, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide reduces striatal adenylate cyclase activity. Fipexide has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide is used for senile dementia research. Fipexide acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection .
    Fipexide (Standard)
  • HY-147149

    Others Neurological Disease
    BPN-15477 is a potent SMC (splicing modulator compound) that restores correct splicing of ELP1 (Elongator complex protein 1) exon 20. BPN-15477 corrects splicing of the ELP1 transcript, significantly increases the level of functional protein in vivo in all tissues, including brain. BPN-15477 can be used for frontotemporal dementia research .
    BPN-15477
  • HY-P99688

    AL001

    Neurotensin Receptor Cancer
    Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .
    Latozinemab
  • HY-107203

    HWA 285

    Phosphodiesterase (PDE) Neurological Disease Inflammation/Immunology
    Propentofylline is a xanthine-derivative that inhibits adenosine uptake and blocks phosphodiesterase activity. Propentofylline has neuroprotective, antiproliferative, and anti-inflammatory effects that improve cognition and dementia severity in patients with Alzheimer's disease or vascular dementia.
    Propentofylline
  • HY-151928

    JNK Neurological Disease
    JNK3 inhibitor-3 (compound 15g) is a selective, BBB permeable and orally active c-Jun N-terminal kinase 3 (JNK3) inhibitor. JNK3 inhibitor-3 has inhibitory activities to JNK1, JNK2 and JNK3 with IC50 values of 147.8, 44.0 and 4.1 nM, respectively. JNK3 inhibitor-3 significantly improves the memory in mouse dementia model. JNK3 inhibitor-3 can be used for the research of Alzheimer’s disease .
    JNK3 inhibitor-3
  • HY-128892
    EN6
    3 Publications Verification

    Autophagy Neurological Disease
    EN6 is a small-molecule in vivo autophagy activator that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase. EN6-mediated modification of ATP6V1A uncouples v-ATPase from Rag, leading to inhibition of mTORC1 signalling, increased lysosomal acidification, and activation of autophagy. EN6 also scavenges TDP-43 aggregates (causative agents of frontotemporal dementia) in a lysosome-dependent manner .
    EN6
  • HY-106933

    Adrenergic Receptor Neurological Disease
    Dabelotine is an adrenergic receptor agonist used in the study of dementia .
    Dabelotine
  • HY-151527
    PI3K/Akt/CREB activator 1
    1 Publications Verification

    Akt PI3K Epigenetic Reader Domain Neurological Disease
    PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD) .
    PI3K/Akt/CREB activator 1
  • HY-101669

    Calcium Channel Neurological Disease
    TDN345 is a Ca 2+ antagonist, used for the treatment of vascular and senile dementia including Alzheimer's disease.
    TDN345
  • HY-133025

    Others Neurological Disease
    FK962 is an enhancer of somatostatin release, exerts cognitive-enhancing actions. Anti-dementia properties .
    FK962
  • HY-113407

    Endogenous Metabolite Neurological Disease
    D-Fructose 6-phosphate is an endogenous metabolite present in Saliva that can be used for the research of Lewy Body Dementia .
    D-Fructose-6-phosphate
  • HY-P1707A

    Tau Protein Neurological Disease
    Tau protein (592-597), human TFA is a peptide fragment of human Tau protein. The dysfunction of Tau protein is involved in neurodegeneration and dementia .
    Tau protein (592-597), human TFA
  • HY-17368
    Rivastigmine
    1 Publications Verification

    ENA 713 free base; SDZ-ENA 713 free base

    Cholinesterase (ChE) Neurological Disease
    Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .
    Rivastigmine
  • HY-113228
    Isocitric acid
    1 Publications Verification

    Endogenous Metabolite Neurological Disease
    Isocitric acid is an endogenous metabolite present in Saliva and Cellular_Cytoplasm that can be used for the research of Alzheimer's Disease, Lewy Body Dementia and Anoxia .
    Isocitric acid
  • HY-11017
    Rivastigmine tartrate
    1 Publications Verification

    ENA 713; SDZ-ENA 713

    Cholinesterase (ChE) Neurological Disease
    Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .
    Rivastigmine tartrate
  • HY-17368S1

    (Rac)-ENA 713-d6 free base; (Rac)-SDZ-ENA 713-d6 free base

    Isotope-Labeled Compounds Cholinesterase (ChE) Neurological Disease
    (Rac)-Rivastigmine-d6 is a labelled racemic Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease[1][2].
    (Rac)-Rivastigmine-d6
  • HY-17552S

    Choline Alfoscerate-d9; Alpha-GPC-d9; L-α-GPC-d9

    Isotope-Labeled Compounds Cholinesterase (ChE) Endogenous Metabolite Neurological Disease
    sn-Glycero-3-phosphocholine-d9 is the deuterium labeled sn-Glycero-3-phosphocholine. sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia[1][2].
    sn-Glycero-3-phosphocholine-d9
  • HY-100618
    Hispidin
    1 Publications Verification

    PKC Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Hispidin, a PKC inhibitor and a phenolic compound from Phellinus linteus, has been shown to possess strong anti-oxidant, anti-cancer, anti-diabetic, and anti-dementia properties .
    Hispidin
  • HY-17368R

    ENA 713 (free base)(Standard); SDZ-ENA 713 (free base)(Standard)

    Cholinesterase (ChE) Neurological Disease
    Rivastigmine (Standard) is the analytical standard of Rivastigmine. This product is intended for research and analytical applications. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .
    Rivastigmine (Standard)
  • HY-17368S2

    ENA 713-d3 hydrochloride; SDZ-ENA 713-d3 hydrochloride

    Cholinesterase (ChE) Isotope-Labeled Compounds Neurological Disease
    Rivastigmine-d3 hydrochloride is deuterated labeled Rivastigmine (HY-17368). Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .
    Rivastigmine-d3 hydrochloride
  • HY-N0115
    Gastrodin
    Maximum Cited Publications
    7 Publications Verification

    Gastrodine

    Others Neurological Disease Inflammation/Immunology
    Gastrodin, a main constituent of a Chinese herbal medicine Tianma, has been known to display anti-inflammatory effects. Gastrodin, has long been used for treating dizziness, epilepsy, stroke and dementia.
    Gastrodin
  • HY-11017R

    ENA 713 (Standard); SDZ-ENA 713 (Standard)

    Cholinesterase (ChE) Neurological Disease
    Rivastigmine (tartrate) (Standard) is the analytical standard of Rivastigmine (tartrate). This product is intended for research and analytical applications. Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .
    Rivastigmine tartrate (Standard)
  • HY-17555A

    Centrophenoxine

    nAChR iGluR Neurological Disease
    Meclofenoxate (Centrophenoxine) is an ester synthesized from DMAE and pCPA, which has the activity of stimulating memory and improving cognition .
    Meclofenoxate
  • HY-160236

    Others Neurological Disease
    3-(3-Sulfooxyphenyl)propanoic acid (compound M14) is a metabolite of an anti-dementia agent namely echinacoside. 3-(3-Sulfooxyphenyl)propanoic acid has the potential for the research of neurological and behavioral disorders .
    3-(3-Sulfooxyphenyl)propanoic acid
  • HY-123272

    5-HT Receptor Neurological Disease
    E6801 is a 5-HT6 receptor agonist that improves recognition memory by jointly modulating cholinergic and glutamatergic neurotransmission. E6801 can be used in studies of dementia, depression, obesity, epilepsy, etc .
    E6801
  • HY-19225

    KA-672 hydrochloride; Anseculin hydrochloride

    Others Neurological Disease
    Ensaculin is an NMDA receptor channel blocker. Ensaculin has neuroprotective effects in NMDA toxicity models and promotes neuronal growth in primary cultures of rat brain cells. Ensaculin has the potential to be developed as an anti-dementia drug that acts on various neurotransmitter systems .
    Ensaculin
  • HY-N0115R

    Others Neurological Disease Inflammation/Immunology
    Gastrodin (Standard) is the analytical standard of Gastrodin. This product is intended for research and analytical applications. Gastrodin, a main constituent of a Chinese herbal medicine Tianma, has been known to display anti-inflammatory effects. Gastrodin, has long been used for treating dizziness, epilepsy, stroke and dementia.
    Gastrodin (Standard)
  • HY-N7109

    PI3K Endogenous Metabolite Neurological Disease
    Erucic acid, a monounsaturated fatty acid (MUFA), is isolated from the seed of Raphanus sativus L. Erucic acid can readily cross the blood-brain barrier (BBB), it has been reported to normalize the accumulation of very long-chain fatty acids in the brain. Erucic acid can improve cognitive impairment and be effective against dementia .
    Erucic acid
  • HY-17552
    sn-Glycero-3-phosphocholine
    1 Publications Verification

    Choline Alfoscerate; Alpha-GPC; L-α-GPC

    Cholinesterase (ChE) Endogenous Metabolite Neurological Disease
    sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia .
    sn-Glycero-3-phosphocholine
  • HY-N10781

    Cholinesterase (ChE) Cardiovascular Disease Neurological Disease Cancer
    Isograndifoliol is a selective inhibitor of butyrylcholinesterase (BChE) with an IC50 value of 0.9 μM. And Isograndifoliol moderately inhibits acetylcholinesterase (AChE) with an IC50 value of 342.9 μM. Isograndifoliol also has vasorelaxant effect and anti-tumor effect. Isograndifoliol can be used for research against dementia caused by neurodegenerative diseases .
    Isograndifoliol
  • HY-14744A
    Levamlodipine besylate
    1 Publications Verification

    (S)-Amlodipine besylate; Levoamlodipine besylate

    Calcium Channel SOD Cardiovascular Disease
    Levamlodipine besylate ((S)-Amlodipine besylate) is an orally active calcium channel blocker with antioxidant and vasodilatory properties. Levamlodipine besylate can reduce serum malondialdehyde (MDA) levels, increase superoxide dismutase (SOD) activity, and improve oxidative stress. Levamlodipine besylate can be used for research on vascular dementia, hypertension, and cerebrovascular diseases .
    Levamlodipine besylate
  • HY-B0763
    Ibudilast
    5 Publications Verification

    KC-404; AV-411; MN-166

    Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
    Ibudilast
  • HY-103479

    Acyltransferase Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.
    GOAT-IN-1
  • HY-W453397

    Ligands for Target Protein for PROTAC Neurological Disease
    Aberrant tau ligand 1 is a ligand for tau proteins with abnormal forms. Aberrant tau ligand 1 can be used for synthesis of PROTAC aberrant Tau degrader QC-01-175 (HY-134850) .
    Aberrant tau ligand 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: